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Interleukin 2 (IL-2), a  lymphokine produced by thymus-derived lymphocytes, 
has  been  shown  (1,  2)  to  have  a  variety  of immunologic  functions  in  vitro 
including an  important  role in regulating  the growth and differentiation of T 
lymphocytes. It has also been shown (3-5) that in vivo administration of IL-2 can 
modify immune responses in nude and normal mice. However, the effects of IL- 
2 on immune responses under control of Ir genes have not been tested. 
We have been studying the H-2-1inked Ir gene control of the antibody and T 
cell responses to sperm whale myoglobin, a model globular protein antigen. Both 
the T  cell proliferative response  and  the antibody response  to myoglobin are 
controlled in parallel by H-2-1inked genes (6, 7). The availability of large amounts 
of highly purified recombinant IL-2 (8) prompted us to evaluate the influence 
of  IL-2  on  immune  responses  under  Ir  gene  control.  For  this  purpose,  we 
immunized  low- and  high-responder mice with  myoglobin together with  IL-2, 
and  evaluated its effects on antibody responses.  The results  show  that  in  vivo 
administration  of IL-2 with  myoglobin significantly enhances the antibody re- 
sponse in Iow-responder mice, to levels similar to those in high-responder mice. 
Materials and  Methods 
Mice.  B10.BR/SgSn and B10.D2/nSn were obtained from The Jackson Laboratory, 
Bar  Harbor,  ME.  BI0.D2/nSn  nu/nu  were  provided by  D.  Bolte of the  NIH.  Small 
Animal Resources facility. All mice were between 8 wk and 6 mo of age at the time of 
immunization. 
Antigen.  The  major chromatographic component,  IV,  of sperm  whale  myoglobin, 
purified as described previously (6), was used throughout the studies. 
IL-2.  The recombinant IL-2 for these studies was kindly supplied by the Cetus Corp. 
(Emeryville, CA). Homogeneity has been demonstrated by the presence of a single band 
on  sodium  dodecyl  sulfate  (SDS)-polyacrylamide gels  with  a  molecular  mass  of  15 
kilodaltons (8). The endotoxin level in the purified preparations was negligible, <0.1 ng 
per 106 U IL-2, as measured in a standard Limulus assay. 
Immunizations  and  Antimyoglobin Antisera.  Mice  were  immunized  with  100  #g  of 
myoglobin in complete Freund's adjuvant with or without IL-2, and bled serially from 10 
d to 46 d later. The IL-2 and antigen were emulsified together in the adjuvant. 
Enzyme-linked Immunoabsorbent Assay (ELISA) for Antimyoglobin.  Concentration of anti- 
bodies in the sera was measured by solid-phase ELISA, as described previously (7, 9). Data 
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FIGURE  1.  Time course ofantimyoglobin antibody production by B10.BR (Q, O) and B10.D2 
(B, ['7) mice after an  immunization with  100 t~g of sperm  whale myoglobin, together with 
50,000  U  IL-2 (closed symbols) or without IL-2 (open symbols). B10.BR is a  Iow-responder 
strain,  and  B10.D2  is  a  congenic  high-responder strain  to  sperm  whale  myoglobin.  Each 
antiserum was tested individually for the concentration of antimyoglobin antibody by ELISA. 
Results represent the geometric means and standard errors for five mice of each group. Note 
logarithmic scale. 
obtained from the ELISA were calculated with the log-logit formulation using a program 
written by Dr.  Robert Yarchoan  (National  Cancer Institute.  Bethesda,  MD) for a Wang 
2200 computer (Wang Laboratories, Lowell, MA). 
Results and Discussion 
The  antibody  response  and  in  vitro  T  cell  proliferative  response  to  sperm 
whale myoglobin are under control oflr genes linked to the mouse H-2 complex 
(6, 7, 10). To investigate possible effects of exogenous IL-2 on the antimyoglobin 
response, high- (H-2  d) and low- (H-2  k) responder congenic strains of mice were 
immunized with sperm whale myoglobin, with or without highly purified recom- 
binant  IL-2, and the concentration  of antimyoglobin antibodies in the sera was 
measured. IL-2 was incorporated in the adjuvant emulsion with antigen in order 
to provide a high local concentration over an extended period. 
Figs.  1 and  2  show that  the administration  of high-dose  IL-2  can  markedly 
increase (10-50-fold) the antibody response to myoglobin in low-responder mice, 
but not in high-responder  mice. Without IL-2, the B10.BR mice (H-2  k) showed 
>10-foid lower response,  compared with the B10.D2  mice (H-2a).  In contrast, 
injection  of IL-2  with  myoglobin significantly enhanced  the antimyoglobin  re- 
sponse only in  B10.BR mice,  and  raised antibody  levels to the  ranges  seen in 
high-responder  B10.D2 mice. The enhancement  was seen over the entire  time 
course of the response, but no change in kinetics was noted (Fig. 1). The optimum 
dose of IL-2 was 50,000-100,000  U  mixed with the antigen (Fig. 2). 
Since  the  preparation  of recombinant  IL-2  includes  mannitol  and  SDS,  we 
tested the effect of the vehicle, which has the same amount of mannitol and SDS, 
on the antimyoglobin response (Fig. 3).  Vehicle alone did not increase antibody 
response  in  either  B10.BR  or  B10.D2  mice.  Also,  the  influence  of possible 
endotoxin  contamination  was  tested,  although  endotoxin  was  not  detectable 
(<0.1  ng in  106  U  IL-2) in the preparation  of IL-2. There was no influence on 
the antimyoglobin antibody response with the mixture of vehicle and the maxi- KAWAMURA  ET  AL.  BRIEF  DEFINITIVE  REPORT  383 
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FIGURE 2.  Dose-response curve of the effect of IL-2 on antimyoglobin antibody production 
by B10.BR (0) and B10.D2 (ll) mice. Five mice for each group were immunized with 100 #g 
of sperm whale myoglobin, together with, or without, the indicated dose of IL-2 in Freund's 
adjuvant, and bled 30 d  later. Results represent the geometric means and standard errors for 
five mice of each group. Note logarithmic scale. 
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FIGURE  3.  The  effect of the vehicle used  for  dissolving IL-2  on antimyoglobin antibody 
production by B10.BR and B10.D2 mice. Five mice in each group were immunized with 100 
#g of sperm whale myoglobin (Mb) together with the indicated reagent. The dose of IL-2 was 
25,000  U/mouse.  Mice were bled  20 d  after the immunization. Each point represents the 
concentration ofantimyoglobin antibody of one mouse, and the geometric means and standard 
errors for five mice of each group are shown with bars. Note logarithmic scale. 
mum  possible  dose  of contaminating  endotoxin  (1  pg)  (data  not  shown).  In 
addition, IL-2 alone, without myoglobin, did not stimulate B 10.BR mice to make 
antimyoglobin antibodies (data not shown). Thus, this study showed that in vivo 
administration of IL-2 can increase the magnitude of the antimyoglobin antibody 
response in low-responder mice. 
The mechanism by which IL-2 enhances the antibody response to myoglobin 
in vivo in low-responder mice is unknown. Since B10.BR mice are low responders, 
not  nonresponders,  they  do  make  a  low but  detectable  T  cell  and  antibody 
response to myoglobin (6,  7, 9,  10). IL-2 may expand the low T  cell help, or it 
may act directly on B cells, as has recently been shown possible in other systems 
(11-13). To test the latter possibility, we examined the effect of IL-2 mixed with 
antigen on the antibody response in athymic nude mice. B10.BR nudes were not 
available,  so these experiments  were performed  with  B10.D2  nude  mice only. 
These are congenic to both of the strains  used, and are of the high-responder 
H-2  d haplotype,  so  they  could  respond  to  myoglobin,  except  for  the  lack  of 384  KAWAMURA  ET  AL.  BRIEF  DEFINITIVE REPORT 
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FIGURE 4.  The lack of effect of IL-2 on antimyoglobin (anti-Mb) antibody production by 
B10.D2 nude mice. See Fig. 3 for experimental details. The data in Fig. 3 and Fig. 4 are part 
of the same large experiment. Therefore, Fig. 3 serves as a positive control for Fig. 4. 
mature T  cells. When B10.D2 nude mice were immunized with myoglobin with 
or  without  IL-2,  there  was  no  response  and  no  effect of IL-2  (Fig.  4).  The 
experiment of Fig. 3 was part of the same experiment as Fig. 4, and serves as a 
positive control. This result shows that the IL-2 effect requires T  cells, but does 
not directly demonstrate that the IL-2 acts on T  cells rather than B cells or both. 
In contrast, Stotter et al. (3) reported that IL-2 allowed in vivo induction of T 
helper cells against heterologous erythrocytes in athymic (nu/nu)  mice. Differ- 
ences between  soluble and particulate antigen, and between recombinant and 
cell culture IL-2 may explain this discrepancy. 
As the response may remain T-dependent even if IL-2 acts directly on B cells 
to enhance the response, these experiments with athymic B10.D2 nude mice do 
not exclude the possibility that IL-2 acts directly on B cells in euthymic B10.BR 
mice. However, given its recognized T  cell growth promoting activity, the IL-2 
in our experiments probably also acts by expanding the low levels of T  cell help 
known (6, 7, 9,  10) to exist in the low responder. Further, it has been shown (9, 
10) that T  cells specific for carrier (e.g. fowl y-globulin) coupled to myoglobin, 
overcome  the  Ir  gene-controlled  low  responsiveness.  Thus,  the  antibody re- 
sponse to myoglobin controlled by Ir genes seems to be dependent on helper T 
cell activation, as seen in many other studies (14,  15),  but not known on B cell 
repertoire. 
Therefore, a reasonable, but not exclusive interpretation of the results is that 
a  low T  cell response in vivo in the low responder is enhanced by IL-2, and is 
reflected  in  an  increased  antibody response.  In  contrast,  if the  higher  T  cell 
response induced by myoglobin in the high responder is not limiting, enhance- 
ment of this by IL-2 would not result in an increase in antibody response. 
The antibody response to myoglobin in B10.BR mice is normally so low that 
we have not been able to analyze its fine specificity. Thus, we cannot tell whether 
the IL-2 enhances responses to epitopes to which B10.BR mice already respond 
at a  low level, or whether it induces responses to new epitopes.  Assuming that 
IL-2, as a nonspecific mediator, affects magnitude of response but not specificity, 
then its use to amplify the response in B10.BR  mice may allow the analysis of 
their antibody specificity. However, as noted, this assumption may not be valid. 
The half-life of IL-2 in the serum  is <5  rain (5), and thus administration of 
large amounts are required to demonstrate in vivo effects. The administration 
of IL-2, together with antigen in the emulsion with Freund's adjuvant, probably KAWAMURA ET  AL.  BRIEF  DEFINITIVE  REPORT  385 
prolongs  the  local  half-life  of  IL-2  considerably,  and  thus  a  relatively  high 
concentration  of IL-2  can  be  maintained  locally,  where  T  cells,  B  cells,  and 
macrophages are responding to antigen. 
This is the  first report that  demonstrates  that  the administration  of IL-2  in 
vivo, with  soluble protein  antigen,  can  increase  the antibody response  in  low- 
responder mice. Although IL-2 may have been one of the active components of 
allogeneic  effect factor  (16),  it  was not  the  sole component,  since  that  factor 
bore  major  histocompatibility  complex  antigenic  determinants,  and  had 
different  immunological  properties.  Concurrently,  Durum  et  al.  (17)  discov- 
ered  a  similar  effect  with  IL-1.  They  immunized  low-responder  mice  with 
poly(Glu60,Alas0,Tyrl0)  (GAT),  together  with  IL-1  in  emulsion  with  Freund's 
adjuvant, and discovered that T  cells from those mice proliferated as much as T 
cells from high-responder mice. In both our and their experiments, lymphokines 
(IL-1  and  IL-2)  changed  the  low-responder  phenotype  into  a  high-responder 
phenotype.  In  fact,  the  mechanism  of the  IL-1  effect may be to induce  IL-2, 
although in the case of GAT, it might also have a contrasuppressor effect (17). 
The results of these experiments indicate that the administration  of IL-2 is a 
potential method for manipulating immune responses that are under the control 
of Ir genes. It thus may allow the analysis of the response of low-responder mice 
more easily, by magnifying small responses. Several studies (18) in humans show 
that Ir genes influence the sensitivity of individuals to vaccination, and that the 
pathophysiology of some diseases is influenced by Ir genes.  In clinical use, this 
method may provide a  more effective way to successfully immunize  with weak 
antigens (and possibly tumor antigens), or in immunodeficient patients. 
Summary 
We studied the effect of purified  interleukin  2 (IL-2),  made by recombinant 
DNA  techniques,  on  the  serum  antibody response  to  myoglobin in  high-  and 
low-responder  mice.  Previous  studies  (6,  7)  have  shown  that  this  response  is 
controlled by H-2-1inked Ir genes. The  IL-2 was emulsified with the antigen in 
complete Freund's adjuvant to provide a  sustained high  local concentration.  In 
low-responder  B10.BR mice,  a  single  dose (optimum  50,000  U) resulted  in  a 
consistent  10-50-fold increase in  specific serum antibody throughout  the time 
course of the response, from  10 d  to 46 d  after immunization.  In contrast,  no 
effect of IL-2 was seen in congenic high-responder B10.D2 mice. With IL-2, the 
low-responder mice achieved specific antibody levels comparable to those of high 
responders.  Vehicle alone had  no effect, and  IL-2 alone,  without antigen,  did 
not induce myoglobin-specific antibody. No effect of IL-2 was seen in athymic 
nude  mice of high-responder  H-2  haplotype.  The  effect of IL-2  may be on a 
small number of responding T  cells in the low responder mice, but it is possible 
that  IL-2 also acts directly on  B cells in a  response that  remains  T-dependent, 
and therefore is not observed in athymic mice. We suggest that IL-2 may enhance 
suboptimal T  cell help in the low responder,  whereas help is not limiting in the 
high  responder.  This approach  may enable the study of antibody responses in 
low responders otherwise too weak to analyze, and may be useful in producing 
antibodies  to poorly immunogenic  antigens.  Potential  clinical  uses include  im- 
munization with weak antigens in normal patients, or with any antigen in certain 
immunodeficient patients. 386  KAWAMURA ET  AL.  BRIEF  DEFINITIVE  REPORT 
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